Q1 Earnings Forecast for Immunic Issued By William Blair

Key Points

• William Blair predicts Immunic will report a Q1 2026 earnings per share of ($0.16), while the consensus estimate for the full year is ($0.94) per share.
• Immunic's recent quarterly earnings report showed a loss of ($0.20) EPS, missing analysts' estimates by ($0.02).
• Immunic currently has a Buy consensus rating, with price targets ranging from $5.00 to $10.00 among various analysts.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Immunic in a note issued to investors on Thursday, August 7th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.16) for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic's Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.17) EPS.

Other equities analysts have also issued reports about the company. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Friday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday, May 1st. Finally, B. Riley reaffirmed a "buy" rating and issued a $5.00 price objective (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. One analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $7.50.

Immunic Price Performance

Shares of Immunic stock traded down $0.01 during midday trading on Monday, reaching $0.91. The company had a trading volume of 511,417 shares, compared to its average volume of 1,237,195. The stock has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.97. The firm has a market cap of $89.28 million, a PE ratio of -0.74 and a beta of 1.39. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02).

Institutional Investors Weigh In On Immunic

A number of hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. bought a new stake in Immunic in the fourth quarter worth approximately $37,000. Renaissance Technologies LLC increased its holdings in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. Barclays PLC bought a new stake in Immunic in the fourth quarter worth approximately $84,000. 683 Capital Management LLC increased its holdings in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.